{"filings":[{"id":696196,"accession_number":"0001964738-26-000031","cik":1964738,"company_name":"Solventum Corp","ticker":"SOLV","form_type":"8-K","filed_at":"2026-05-27T20:23:24+00:00","items":["5.02","9.01"],"status":"ready","headline":"Solventum adopts new Executive Severance Plan effective June 1, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Provides 12 months base salary plus prorated incentive for CEO direct reports; current execs retain 18 months for 2 years.","Lump-sum COBRA premium payment for CEO and direct reports; forfeiture of post-effective date equity awards.","Pre-effective date awards receive limited accelerated vesting based on service fraction.","Plan supersedes prior plan dated April 1, 2024; grandfathered rights preserved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":13100666943.182238,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":554686,"accession_number":"0001964738-26-000027","cik":1964738,"company_name":"Solventum Corp","ticker":"SOLV","form_type":"8-K","filed_at":"2026-05-20T20:14:28+00:00","items":["5.07"],"status":"ready","headline":"Solventum shareholders elect four directors, approve say-on-pay, ratify auditor at 2026 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Class II directors Albán, DeVore, Edwards, Harris with majority support (approx 114M-115M for, 27M-28M against).","Advisory vote on named executive officer compensation approved: 105.2M for, 36.6M against.","Ratified PricewaterhouseCoopers as independent auditor for FY 2026: 156.4M for, 0.5M against.","Broker non-votes of ~14.8M shares on director elections and say-on-pay; none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":13100666943.182238,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96967,"accession_number":"0001964738-26-000022","cik":1964738,"company_name":"Solventum Corp","ticker":"SOLV","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Solventum Q1 sales $2.0B (organic +2.1%), adj. EPS $1.48, affirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported sales $2.007B, down 3.0%; organic sales up 2.1%, ahead of expectations.","GAAP diluted EPS $0.07 vs $0.78; adjusted diluted EPS $1.48, up 10.6% YoY.","Operating cash flow $(189)M, free cash flow $(273)M, vs $(80)M FCF a year ago.","Affirms FY2026 organic sales growth and FCF guidance; adj. EPS expected toward high end.","CEO Bryan Hanson cited strong execution and commercial momentum, reinforcing full-year confidence."],"consensus_eps_estimate":null,"consensus_eps_actual":0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":2007000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":13100666943.182238,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111355,"accession_number":"0001964738-26-000013","cik":1964738,"company_name":"Solventum Corp","ticker":"SOLV","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Solventum CAO Mary Wilcox to retire upon successor appointment","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mary Wilcox notified intent to retire and resign as Chief Accounting Officer on March 20, 2026.","Wilcox will remain until a successor is found and appointed.","No successor named yet; search process underway.","Wayde McMillan remains EVP and CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":13100666943.182238,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111354,"accession_number":"0001964738-26-000005","cik":1964738,"company_name":"Solventum Corp","ticker":"SOLV","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Solventum reports Q4 2025 sales $2B, organic sales +3.5%; full-year adjusted EPS $6.11, down 8.8% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 reported sales $1,998M (-3.7% YoY); organic sales +3.5% driven by MedSurg and Dental.","GAAP diluted EPS $0.36; adjusted diluted EPS $1.57 (+11.3% YoY).","Full-year 2025 adjusted EPS $6.11 (down 8.8% from $6.70); free cash flow -$10M vs $805M in 2024.","Introduced 2026 full-year guidance for organic sales growth, adjusted EPS, and free cash flow.","CEO Bryan Hanson: full-year 2025 results ahead of expectations; solid progress toward long-range plan."],"consensus_eps_estimate":null,"consensus_eps_actual":8.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":8325000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13100666943.182238,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127965,"accession_number":"0001964738-25-000094","cik":1964738,"company_name":"Solventum Corp","ticker":"SOLV","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Solventum CEO reviews first standalone year; cites volume growth, acquisitions, $1B buyback","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Six consecutive quarters of positive volume growth; full-year 2025 outlook raised multiple times.","Completed sale of Purification & Filtration segment; used proceeds to reduce debt and strengthen balance sheet.","First strategic acquisition: Acera Surgical, expanding Advanced Wound Care portfolio.","Announced $1 billion share repurchase program, balancing capital allocation strategy.","Exited over 35% of 3M transition service agreements; progressing on supply chain separation and ERP cutover."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":13100666943.182238,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127964,"accession_number":"0001964738-25-000089","cik":1964738,"company_name":"Solventum Corp","ticker":"SOLV","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Solventum Q3 organic sales +2.7%; raises FY adj. EPS guidance to $5.98-$6.08","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 reported sales $2.1B (+0.7% YoY); organic sales +2.7% driven by Dental Solutions and HIS.","GAAP diluted EPS $7.22 (includes large non-recurring gains); adjusted diluted EPS $1.50, down 8.5% YoY.","Adjusted operating margin 20.6% down 220bps due to tariffs, public-company costs, growth investments.","Full-year adj. EPS guidance raised to $5.98-$6.08; organic sales growth at high end of +2-3%.","Announces 4-year 'Transform for the Future' initiative; operating cash flow $75M, FCF -$22M."],"consensus_eps_estimate":null,"consensus_eps_actual":8.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":6327000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13100666943.182238,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127963,"accession_number":"0001628280-25-045731","cik":1964738,"company_name":"Solventum Corp","ticker":"SOLV","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Solventum appoints Heather Knight as Chief Commercial Officer; Chris Barry to depart","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Heather Knight appointed to new Chief Commercial Officer role effective Nov 10, 2025, overseeing MedSurg, Dental, Health Information Systems.","Ms. Knight previously COO at Baxter International; brings 30+ years MedTech leadership.","Chris Barry, EVP & Group President of MedSurg, will depart Dec 31, 2025, and receive severance under the Solventum Executive Severance Plan.","Knight will report directly to CEO Bryan Hanson.","Barry's outstanding equity awards will be treated per applicable agreements and Severance Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13100666943.182238,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144745,"accession_number":"0001964738-25-000084","cik":1964738,"company_name":"Solventum Corp","ticker":"SOLV","form_type":"8-K","filed_at":"2025-09-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Solventum upsizes note tender offers to $2B, prices purchases at premiums","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Increased aggregate cap from $1.75B to $2B; Pool 1 max raised to $1.5B and Tender SubCap to $650M.","Financing condition (sale of purification/filtration business to Thermo Fisher) has been satisfied.","Accepted ~$650M of 5.450% 2027 notes (69.35% proration) and ~$797M of 5.400% 2029 notes (61.24% proration).","In Pool 2, accepted ~$458M of 6.000% 2064 notes and ~$22M of 5.900% 2054 notes (2.58% proration).","Total consideration includes $30 per $1,000 early tender payment; settlement expected Sept. 10, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":13100666943.182238,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144744,"accession_number":"0001964738-25-000078","cik":1964738,"company_name":"Solventum Corp","ticker":"SOLV","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["2.01","7.01","9.01"],"status":"ready","headline":"Solventum completes $4.0B sale of Purification & Filtration business to Thermo Fisher","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Completed sale of P&F business to Thermo Fisher for $4.0B cash on September 1, 2025.","Net proceeds of $3.4B primarily to pay down outstanding debt; accelerates debt reduction.","Updated FY2025 guidance: adjusted EPS raised to $5.88-$6.03 from $5.80-$5.95.","Net interest expense now expected at $400M (down from $450M); operating margin toward 20%-21% high-end.","Organic sales growth unchanged at +2.0% to +3.0%; free cash flow maintained at $450M-$550M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":13100666943.182238,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144743,"accession_number":"0001964738-25-000073","cik":1964738,"company_name":"Solventum Corp","ticker":"SOLV","form_type":"8-K","filed_at":"2025-08-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Solventum commences $1.75B note tender offers contingent on Thermo Fisher deal proceeds","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Up to $1.75B aggregate purchase price: Pool 1 ($1.25B) covers 2027-2031 notes, Pool 2 ($500M) covers 2054 & 2064 notes.","2027 Notes have $500M sublimit; early tender payment of $30 per $1,000 principal for all series.","Condition: Solventum must receive and repatriate proceeds from sale of purification & filtration business to Thermo Fisher (announced June 25, 2025).","Tender offers expire Sept 22, 2025; early tender deadline Sept 5, 2025; early settlement expected Sept 10, 2025.","Lead dealer managers: J.P. Morgan, Morgan Stanley, Barclays, Goldman Sachs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13100666943.182238,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144742,"accession_number":"0001140361-25-031512","cik":1964738,"company_name":"Solventum Corp","ticker":"SOLV","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Solventum announces secondary offering of 8.8M shares by 3M for ~$648M gross proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["3M sells 8,800,000 shares of Solventum common stock in secondary offering.","Gross proceeds to 3M approximately $648 million; Solventum receives no proceeds.","Offering priced at ~$73.64/share; expected to close Aug 15, 2025.","Underwriters are Goldman Sachs & Co. LLC and BofA Securities.","Shares offered pursuant to existing shelf registration statement on Form S-3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":13100666943.182238,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144741,"accession_number":"0001140361-25-030803","cik":1964738,"company_name":"Solventum Corp","ticker":"SOLV","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Solventum amends purification & filtration sale to Thermo Fisher; consideration reduced to ~$4.0B","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Amended agreement on June 25, 2025 excludes drinking water filtration business; cash consideration cut from $4.1B to ~$4.0B.","Pro forma net income for H1 2025: $86M (vs historical $227M) after removal of business and transaction adjustments.","Pro forma net income for FY2024: $1,677M (vs historical $479M) including $1.56B estimated pre-tax gain on sale.","Net cash proceeds estimated at $3.89B after costs, working capital, and debt adjustments; proceeds to be used for debt paydown.","Transaction expected to close with customary adjustments; ~$98M non-current assets remain due to delayed transfers in certain jurisdictions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13100666943.182238,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144740,"accession_number":"0001964738-25-000062","cik":1964738,"company_name":"Solventum Corp","ticker":"SOLV","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Solventum Q2 sales up 3.9% to $2.2B; raises FY organic growth & EPS guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $0.51; adjusted diluted EPS $1.69 (+8.3% YoY).","Organic sales +2.8%; all segments positive, led by MedSurg and HIS.","Adjusted operating margin expanded 120 bps to 21.9%.","FY 2025 organic sales guidance raised to +2.0%-3.0%; EPS raised to $5.80-$5.95.","Operating cash flow $169M; free cash flow $59M in Q2."],"consensus_eps_estimate":null,"consensus_eps_actual":1.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":4231000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13100666943.182238,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163141,"accession_number":"0001964738-25-000056","cik":1964738,"company_name":"Solventum Corp","ticker":"SOLV","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Solventum amends Thermo Fisher deal to exclude water filtration business; price reduced to ~$4.0B","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Solventum and Thermo Fisher amend agreement to exclude drinking water filtration business; cash consideration cut from ~$4.1B to ~$4.0B.","Amendment expected to decrease complexity and potentially accelerate closing to end of 2025; proceeds still primarily for debt paydown.","Buyer receives up to $75M upon sale of Water Business or after 3-year period.","Keeping Water Business increases estimated annual EPS accretion by 15-20 cents, but reduces gross margin improvement by 200 bps and operating margin by 100 bps.","Updated financial estimates to be provided during Q2 2025 earnings call."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13100666943.182238,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163140,"accession_number":"0001964738-25-000049","cik":1964738,"company_name":"Solventum Corp","ticker":"SOLV","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Solventum Q1 sales up 4.3% organic; GAAP EPS $0.78, adjusted EPS $1.34; guides FY organic growth higher","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $2.07B (+2.6% reported, +4.3% organic); net income $137M (-42.2% YoY).","GAAP diluted EPS $0.78 vs $1.37; adjusted diluted EPS $1.34 vs $2.08.","Operating cash flow $29M (down 93.4%); free cash flow -$80M vs $340M prior year.","Raised FY 2025 organic sales growth outlook by 50bps to +1.5% to +2.5%.","Adjusted operating income margin fell 430bps to 19.7% due to lower gross margins and stand-up costs."],"consensus_eps_estimate":null,"consensus_eps_actual":0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":2070000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":13100666943.182238,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163139,"accession_number":"0001964738-25-000043","cik":1964738,"company_name":"Solventum Corp","ticker":"SOLV","form_type":"8-K","filed_at":"2025-05-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Solventum shareholders elect four directors, approve say-on-pay, ratify auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Four Class I nominees elected: Eisenberg, Mily, Weiland, Wendell — each with >135M votes for.","Advisory say-on-pay approved with 117.4M for (85.6% of votes cast) vs 19.2M against.","Frequency of say-on-pay set to annual; 135.5M votes favored one year (plurality).","Ratification of PwC as independent auditor for FY2025 passed with 152.7M for (99.7% of votes cast)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":13100666943.182238,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181058,"accession_number":"0001964738-25-000015","cik":1964738,"company_name":"Solventum Corp","ticker":"SOLV","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Solventum sells purification and filtration business to Thermo Fisher for $4.1B","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Thermo Fisher to acquire Solventum's purification and filtration business for $4.1B cash, subject to customary adjustments.","Closing expected by end of 2025; conditioned on HSR, other antitrust approvals, and no Material Adverse Effect.","No financing condition for Thermo Fisher; Solventum grants 3-year non-compete and 2-year non-solicit post-close.","Solventum indemnifies Thermo Fisher for pre-closing liabilities and breaches of reps; 3M must confirm tax opinion.","Termination date November 25, 2025, subject to two 3-month extensions if regulatory conditions are unmet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":13100666943.182238,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":181057,"accession_number":"0001964738-25-000013","cik":1964738,"company_name":"Solventum Corp","ticker":"SOLV","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Solventum Q4 2024: GAAP EPS $0.17, adj. EPS $1.41, organic sales +2.3%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $0.17; adjusted EPS $1.41; sales $2,074M (+1.9% reported, +2.3% organic).","GAAP operating income $136M (6.6% margin); adjusted $422M (20.4% margin); MedSurg and Dental drove growth.","Generated $219M cash from operations; free cash flow $92M.","Full-year 2024: sales $8,254M, GAAP EPS $2.76, adjusted EPS $6.70, free cash flow $805M.","Introduced FY 2025 guidance for organic sales growth, adjusted EPS, and free cash flow (specific figures not provided)."],"consensus_eps_estimate":null,"consensus_eps_actual":2.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":8254000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":13100666943.182238,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197939,"accession_number":"0001964738-24-000040","cik":1964738,"company_name":"Solventum Corp","ticker":"SOLV","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Solventum Q3 sales flat at $2.082B; adjusted EPS $1.64, raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $0.70, adjusted EPS $1.64; operating income $275M GAAP, $475M adjusted.","Reported sales +0.4% YoY; organic sales +0.3%; MedSurg and HIS led growth.","Free cash flow $76M; cash from operations $169M.","Full-year organic sales growth, adjusted EPS, and free cash flow guidance raised.","CEO cites consecutive outperformance; supply agreement mark-up impacted margins."],"consensus_eps_estimate":null,"consensus_eps_actual":2.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":6179000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13100666943.182238,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197938,"accession_number":"0001964738-24-000036","cik":1964738,"company_name":"Solventum Corp","ticker":"SOLV","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Solventum adopts enhanced change-in-control severance plan for top executives","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New plan effective Oct 30, 2024 covers CEO, CFO, CAO, and other key executives with enhanced change-in-control severance.","CEO receives cash severance of 2.5x base salary plus target bonus; other executives receive 2.0x.","Qualifying termination includes involuntary discharge or resignation for Good Reason within 6 months before to 18 months after Change in Control.","Plan provides lump-sum COBRA payment, prorated annual bonus at target, full vesting of unvested options/SARs and time-based RSUs.","Also fully vests VIP retirement accounts and offers outplacement services; release of claims required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13100666943.182238,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214104,"accession_number":"0001964738-24-000027","cik":1964738,"company_name":"Solventum Corp","ticker":"SOLV","form_type":"8-K","filed_at":"2024-09-26T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Solventum amends bylaws: advance notice rules eased, nominee resignation requirement removed, indemnification expanded","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Removed requirement for nominating stockholder to disclose info about 'any principal competitor'; financial support disclosure clarified.","Eliminated subsection requiring Board nominees to tender irrevocable resignations effective upon certain Board determinations.","Extended indemnification eligibility to directors, officers, and employees, aligning bylaws with certificate of incorporation.","Board also approved technical and conforming revisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":13100666943.182238,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214103,"accession_number":"0001964738-24-000017","cik":1964738,"company_name":"Solventum Corp","ticker":"SOLV","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Solventum Q2 GAAP EPS $0.51, adj EPS $1.56; raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported sales $2.081B (+0.2% YoY); organic sales +1.3%; MedSurg and HIS drove growth.","GAAP operating margin 11.7%; adjusted operating margin 20.7%; adjusted EPS $1.56.","Generated $355M cash from ops; free cash flow $297M.","Raises full-year 2024 organic sales growth and adjusted EPS guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":1.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":4097000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13100666943.182238,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233327,"accession_number":"0001964738-24-000014","cik":1964738,"company_name":"Solventum Corp","ticker":"SOLV","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Solventum grants equity awards to CEO (102,946 RSUs, 102,946 PSUs, 253,406 inducement PSUs) and CFO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Bryan Hanson: 102,946 RSUs, 102,946 annual PSUs, 253,406 inducement PSUs granted.","CFO Wayde McMillan: 28,509 RSUs, 28,509 annual PSUs, 79,190 inducement PSUs granted.","RSUs vest ratably over 3 years; PSUs tied to 3-year Constant Currency revenue and Adjusted EPS goals.","Inducement PSUs compensate for forfeited equity from prior employer.","All awards under Solventum 2024 Long-Term Incentive Plan, approved May 13, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":13100666943.182238,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233326,"accession_number":"0001964738-24-000012","cik":1964738,"company_name":"Solventum Corp","ticker":"SOLV","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Solventum reports Q1 sales $2.02B, adjusted EPS $2.08; reaffirms 2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Sales $2.016B (+0.2% reported, +0.9% organic); GAAP EPS $1.37, adjusted EPS $2.08.","Operating income $381M GAAP (18.9% margin); adjusted operating income $484M (24.0% margin).","Cash from operations $442M; free cash flow $340M.","Reaffirmed full-year 2024 guidance; spin-off from 3M completed April 1, 2024.","Adjusted results exclude public company and stand-up costs; Q2 onwards reported on stand-alone basis."],"consensus_eps_estimate":null,"consensus_eps_actual":1.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":2016000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":13100666943.182238,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233325,"accession_number":"0001964738-24-000010","cik":1964738,"company_name":"Solventum Corp","ticker":"SOLV","form_type":"8-K","filed_at":"2024-04-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Solventum elects Shirley A. Edwards, former EY partner, to board effective April 12, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Shirley A. Edwards, a former EY Global Client Service Partner (2017-2022), elected to Solventum's Board as a Class II director, term expiring at 2026 annual meeting.","Board found Edwards independent under NYSE listing standards; no related-party transactions requiring disclosure.","Edwards appointed to Audit Committee and Talent Committee; determined to be an audit committee financial expert.","Compensation follows non-employee director policy: annual cash retainer and restricted stock unit grant."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":13100666943.182238,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233324,"accession_number":"0001628280-24-014887","cik":1964738,"company_name":"Solventum Corp","ticker":"SOLV","form_type":"8-K","filed_at":"2024-04-04T23:59:59+00:00","items":["1.01","3.03","5.03","5.02","5.05","8.01","9.01"],"status":"ready","headline":"Solventum completes 3M spin-off, begins trading on NYSE as SOLV","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["80.1% of Solventum shares distributed to 3M stockholders on April 1, 2024; spin-off effective 3:30 a.m. ET.","Solventum reported $8.2B sales in 2023; employs 22,000 people across four business segments.","New executive team: CEO Bryan Hanson, CFO Wayde McMillan, board chair Carrie Cox.","Board reconstituted to 11 members with four committees (Audit, Governance, Talent, Science/Quality).","Separation agreements signed with 3M covering transition services, tax, IP, supply, and trademarks."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":13100666943.182238,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251440,"accession_number":"0001628280-24-010988","cik":1964738,"company_name":"Solventum Corp","ticker":"SOLV","form_type":"8-K","filed_at":"2024-03-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Solventum spin-off from 3M effective; distribution 1:4, record date March 18, completion April 1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Registration statement declared effective March 13, 2024; spin-off proceeding as planned.","3M to distribute 1 share of Solventum common stock for every 4 shares of 3M common stock.","Record date March 18, 2024; distribution expected prior to trading on April 1, 2024.","When-issued trading on NYSE under 'SOLV WI' from March 26-28; regular-way trading 'SOLV' starts April 1.","Investor day scheduled March 19, 2024 in NYC featuring CEO Bryan Hanson and CFO Wayde McMillan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":13100666943.182238,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}